Efficacy and safety of topical trihydroxybenzoic acid glucoside and alpha-arbutin containing formulation along with a sunscreen in facial hyperpigmentation

Authors

  • Siddheshwar Mathpati Mascot Spincontrol India Private Limited, Mumbai, Maharashtra, India
  • Mukesh Gabhane India Medical Affairs, Sun Pharma, Mumbai, Maharashtra, India
  • Poonam Rohira India Medical Affairs, Sun Pharma, Mumbai, Maharashtra, India
  • Priyank Shah India Medical Affairs, Sun Pharma, Mumbai, Maharashtra, India

DOI:

https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20222178

Keywords:

Dark spots, Melanin, Melasma, Pigmentation, Skin brightening, THBG

Abstract

Background: Facial hyperpigmentation is a common presentation in Indian subjects and its treatment is complex. The aim of the study was to evaluate efficacy and safety of a 56-day skincare regimen of topical 3,4,5-trihydroxybenzoic acid glucoside (THBG/Brightenyl®) and α-arbutin containing formulation along with a sunscreen in the management of facial dark spots and melasma.

Methods: Thirty-six female subjects with facial dark spots or melasma who met inclusion/exclusion criteria were enrolled in a prospective, single-arm, study in India. Subjects applied a skin brightening cream containing 10% THBG and 2% α-arbutin twice daily in combination with a sunscreen (SPF=55) once daily; on their whole face for 56 days. Evaluation was carried out at baseline, days 28, 42 and 56 by the same dermatologist and technician. Efficacy was evaluated using mexameter, modified Melasma Area and Severity Index (mMASI), chromameter and cross-polarized light photography.

Results: There was a significant reduction in melanin content (mexametry) and mMASI score compared with the baseline. On chromametry, a significant improvement was seen in skin brightness/lightness (L*) and pigmentation [individual typology angle (ITA°)] demonstrating modification in skin color with an improvement in homogeneity/evenness of the skin tone (ΔE*) from the baseline. At day 56, the total area of the pigmentary spots on the cheeks showed a significant reduction compared to baseline using cross-polarized light photography. The treatment was well tolerated.

Conclusions: This study demonstrates that application of formulation containing 10% THBG and 2% α-arbutin along with a sunscreen is well-tolerated and efficacious in the management of facial hyperpigmentation like dark spots or melasma.

References

Barsh GS. What controls variation in human skin color? PLoS Biol. 2003;1(3):445.

Yamaguchi Y, Brenner M, Hearing VJ. The regulation of skin pigmentation. J Biol Chem. 2007;282(38):27557-61.

Kapoor R, Dhatwalia SK, Kumar R, Rani S, Parsad D. Emerging role of dermal compartment in skin pigmentation: comprehensive review. J Eur Acad Dermatol Venereol. 2020;34(12):2757-65.

Nouveau S, Agrawal D, Kohli M, Bernerd F, Misra N, Nayak CS. Skin Hyperpigmentation in Indian Population: Insights and Best Practice. Indian J Dermatol. 2016;61(5):487-95.

Dogra S, Sarangal R. Pigmentary disorders: An insight. Pigment Int. 2014;1:5-7.

Patel AB, Kubba R, Kubba A. Clinicopathological correlation of acquired hyperpigmentary disorders. Indian J Dermatol Venereol Leprol. 2013;79:367-75.

Sarkar R, Arora P, Garg VK, Sonthalia S, Gokhale N. Melasma update. Indian Dermatol Online J. 2014;5(4):426-35.

Sheth VM, Pandya AG. Melasma: a comprehensive update: part I. J Am Acad Dermatol. 2011;65(4):689-97.

Sheth VM, Pandya AG. Melasma: a comprehensive update: part II. J Am Acad Dermatol. 2011;65(4):699-14.

Hourblin V, Nouveau S, Roy N, de Lacharriere O. Skin complexion and pigmentary disorders in facial skin of 1204 women in 4 Indian cities. Indian J Dermatol Venereol Leprol. 2014;80(5):395-01.

Fulton JE. Utilizing the ultraviolet (UV detect) camera to enhance the appearance of photodamage and other skin conditions. Dermatol Surg. 1997;23(3):163-9.

Gamble RG, Asdigian NL, Aalborg J, Gonzalez V, Box NF, Huff LS, et al. Sun damage in ultraviolet photographs correlates with phenotypic melanoma risk factors in 12-year-old children. J Am Acad Dermatol. 2012;67(4):587-97.

Shankar K, Godse K, Aurangabadkar S, Lahiri K, Mysore V, Ganjoo A, et al. Evidence-based treatment for melasma: Expert opinion and a review. Dermatol Ther (Heidelb). 2014;4(2):165-86.

Fatima S, Braunberger T, Mohammad TF, Kohli I,Hamzavi IH. The role of sunscreen in melasma and postinflammatory hyperpigmentation. Indian J Dermatol. 2020;65:5-10.

Rai R, Shanmuga SC, Srinivas C. Update on photoprotection. Indian J Dermatol. 2012;57(5):335-42.

Davids LM, Wyk JC, Khumalo NP, Jablonski NG . The phenomenon of skin lightening: Is it right to be light? S Afr J Sci. 2016;112:5-5.

Ganceviciene R, Liakou AI, Theodoridis A, Makrantonaki E, Zouboulis CC. Skin anti-aging strategies. Dermatoendocrinol. 2012;4(3):308-19.

Datta HS, Paramesh R. Trends in aging and skincare: ayurvedic concepts. J Ayurveda Integr Med. 2010;1(2):110-3.

Mohiuddin AK. Skin lightening & management of hyperpigmentation. Pharma Sci Analytical Res J. 2019;2:180020.Am J Dermatol Res Rev. 2019;2(2):1-37.

Khanna N, Rasool S. Facial melanoses: Indian perspective. Indian J Dermatol Venereol Leprol. 2011;77(5):552-64.

Chajra H, Redziniak G, Auriol D, Schweikert K, Lefevre F. Trihydroxybenzoic acid glucoside as a global skin color modulator and photo-protectant. Clin Cosmet Investig Dermatol. 2015;8:579-89.

Bandyopadhyay D. Topical treatment of melasma. Indian J Dermatol. 2009;54(4):303-9.

Gallarate M, Carlotti ME, Trotta M, Grande AE, Talarico C. Photostability of naturally occurring whitening agents in cosmetic microemulsions. J Cosmet Sci. 2004;55(2):139-48.

Shankar K, Godse K, Aurangabadkar S, Lahiri K, Mysore V, Ganjoo A, et al. Evidence-based treatment for melasma: expert opinion and a review. Dermatol Ther (Heidelb). 2014;4(2):165-86.

Chajra H, Auriol D, Schweikert K, Jarrin C, Robe P, Redziniak G, et al. International Federation of Societies of Cosmetic Chemists Proceedings of the 23rd IFSCC Conference. Zurich, Switzerland. 2015:21-3.

Lefevre F, Chajra H, Salmassinia P. Brightenyl® - Skin Complexion Bioptimizer. SOFW J. 2015;141:34-7.

Brigtenyl-Toxicology summary sheet. Version 02 date d’application. Givaudan. Available at: https://www.givaudan.com/fragrance-beauty/active-beauty/products/brightenyl. Accessed on 15 March 2022.

Chakraborty AK, Funasaka Y, Komoto M, Ichihashi M. Effect of arbutin on melanogenic proteins in human melanocytes. Pigment Cell Res.1998;11(4):206-12.

Chandorkar NI, Tambe SR, Amin PU, Madankar CS. Alpha Arbutin as a Skin Lightening Agent: A Review. Int J Pharm Res. 2021;13(2):3502-10.

Funayama M, Arakawa H, Yamamoto R, Nishino T, Shin T, Murao S. Effects of alpha- and beta-arbutin on activity of tyrosinases from mushroom and mouse melanoma. Biosci Biotechnol Biochem. 1995;59(1):143-4.

Flashwhite Unispheres®. Flashwhite Unispheres® by Givaudan Active Beauty - Personal Care & Cosmetics. Available at: https://www.ulprospector. com/en/asia/PersonalCare/Detail/831/594872/ Flashwhite-Unispheres). Accessed on 05 December 2021.

Unitamuron H-22®. Available at Unitamuron H-22® by Givaudan Active Beauty - Personal Care & Cosmetics. Available at: https://www.ulprospector. com/en/eu/PersonalCare/Detail/830/34007/Unitamuron-H-22. Accessed on 25 March 2022.

Basit A, Rahman A, Uddin R. Oral tranexemic acid with triple combination cream (flucinolone+ hydroquinone+tretinoin) versus triple combination cream alone in treatment of melasma. J Ayub Med Coll Abbottabad. 2021;33(2):293-8.

Desai S, Ayres E, Bak H, Manco M, Lynch S, Raab S, et al. Effect of a tranexamic acid, kojic acid, and niacinamide containing serum on facial dyschromia: A clinical evaluation. J Drugs Dermatol. 2019;18(5):454-9.

Sarma N, Chakraborty S, Poojary SA, Rathi S, Kumaran S, Nirmal B, et al. Evidence-based review, grade of recommendation, and suggested treatment recommendations for melasma. Indian Dermatol Online J. 2017;8(6):406-42.

Downloads

Published

2022-08-25

Issue

Section

Original Research Articles